logo image
search icon
Global Cell and Gene Therapy Drug Delivery Devices Market

Cell and Gene Therapy Drug Delivery Devices Market Size, Share & Trends Analysis Report By Products (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Pre-Filled Syringe, and Infusion Bags), Commercialized Drugs, Region, And Segment Forecasts, 2023-2031

Report ID : 1025 | Published : 2024-05-22 | Pages: 190 | Format: PDF/EXCEL

The Cell and Gene Therapy Drug Delivery Devices Market Size is valued at 134.0 Thousand in 2022 and is predicted to reach 515.0 Thousand by the year 2031 at a 16.2 % CAGR during the forecast period for 2023-2031.

Key Industry Insights & Findings from the Report:

  • Increasing prevalence of genetic disorders & chronic diseases driving cell and gene therapy drug delivery devices market.
  • An increasing number of FDA approvals for cell & gene therapies & their clinical trials driving cell and gene therapy drug delivery devices market.
  • North America dominated the market and accounted for a global revenue share in 2023.
  • The key challenge for the cell and gene therapy drug delivery devices market is the high costs associated with the manufacturing of these therapies.

Cell and Gene Therapy Drug Delivery Devices Market

The demand for cell and gene therapy drug delivery devices market is enhancing as there is an increase in the number of patients suffering from cancer, diabetes, and other chronic diseases. Therefore, there is a high need of developing affordable and cost-effective cell and gene therapies. Cell and gene therapy is a clinical procedure of modifying genetic material for the treatment of various diseases. Drug Delivery devices have the capacity to perform multiple functions with the highest degree of smartness. Cell and Gene Therapy Drug Delivery Devices are beneficial in the treatment of respiratory diseases, diabetes, and other cardiovascular disorders.

Spreading awareness regarding the benefits of cell and gene therapy drug delivery devices is expected to propel the product demand. Furthermore, fast adoption of advanced technologies, an invention of new devices according to patient’s requirements, increasing government initiatives for research and development of new therapies and devices, high prevalence of chronic diseases, rising number of clinical trials, and creation of smartphone applications will also help to upscale this market. However, the high cost of manufacturing systems, lack of standard therapy protocols, complex procedures, and shortage of skilled professionals are limiting the growth of this market.

Competitive Landscape

Some of The Key Players in The Cell and Gene Therapy Drug Delivery Devices Market:

  • Amgen Inc.
  • Bausch & Lomb Incorporated.
  • Becton, Dickinson and Company
  • Bluebird bio, Inc.
  • Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
  • Dendreon Pharmaceuticals LLC.
  • Helixmith Co., Ltd (ViroMed Co., Ltd)
  • Human Stem Cells Institute
  • Kite Pharma, Inc.
  • Kolon TissueGene, Inc.
  • Novartis AG
  • Orchard Therapeutics plc.
  • Pfizer, Inc.
  • Renova Therapeutics
  • Spark Therapeutics, Inc.
  • uniQure N.V.
  • Vericel Corporation
  • Other Prominent Players

Market Segmentation

The cell and gene therapy drug delivery devices market can be segmented on the basis of products, Commercialized Drugs, and Regions. On the basis of products, the market can be sub-divided into Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Pre-Filled Syringe, and Infusion Bags. On the basis of Commercialized Drugs, the market is sub-segmented into Luxturna, Kymriah, Provenge, Zolgensma, Yescarta, and Strimvelis. Commercialized Drugs segment is expected to dominate this market, as these drugs are modified and prepared according to patient’s requirements. In terms of geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Out of these regions, North America is expected to dominate the market over the forecast period (2019-2031).

Recent Developments:

  • In May 2024, Bluebird Bio, Inc. successfully conducted the initial commercial cell collection for LYFGENIA, an FDA-approved gene therapy for sickle cell disease that was authorized in December 2023. LYFGENIA is the gene therapy that has undergone the most extensive research for sickle cell disease, and it has been examined for the longest period of time compared to other treatments in this field.

 

The Cell and Gene Therapy Drug Delivery Devices Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 134.0 Thousands

Revenue Forecast In 2031

USD 515.0 Thousands

Growth Rate CAGR

CAGR of 18.0 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Thousands and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Products, By Commercialized Drugs

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Bausch & Lomb Incorporated., Amgen Inc., Becton, Dickinson and Company, Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.), Dendreon Pharmaceuticals LLC., Bluebird bio, Inc., Helixmith Co., Ltd (ViroMed Co., Ltd), Human Stem Cells Institute, Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., Kolon TissueGene, Inc., Vericel Corporation, uniQure N.V., and Others

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

   

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Cell and Gene Therapy Drug Delivery Devices Market Snapshot

Chapter 4. Global Cell and Gene Therapy Drug Delivery Devices Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Competitive Landscape & Market Share Analysis

4.7. Major Funding Investments in Cell and Gene Therapy Industry

4.8. COVID 19 Impact Analysis

Chapter 5. Market Segmentation 1: By Products Estimates & Trend Analysis

5.1. By Products & Market Share, 2020 & 2030

5.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Products:

5.2.1. Subretinal Injection Cannula

5.2.2. Extension Tube

5.2.3. Intravenous Catheter

5.2.4. Sterile Insulin Syringe

5.2.5. Pre-Filled Syringe

5.2.6. Infusion Bags

Chapter 6. Cell and Gene Therapy Drug Delivery Devices Market Segmentation 2: By Commercialized Drugs Estimates & Trend Analysis

6.1. By Commercialized Drugs Analysis & Market Share, 2020 & 2030

6.2. Market Size (Value & Volume) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Commercialized Drugs:

6.2.1. Luxturna

6.2.2. Kymriah

6.2.3. Provenge

6.2.4. Zolgensma

6.2.5. Yescarta

6.2.6. Strimvelis

Chapter 7. Cell and Gene Therapy Drug Delivery Devices Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts By Products, 2020-2030

7.1.2. North America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts By Commercialized Drugs, 2020-2030

7.1.3. North America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) estimates and forecasts by country, 2020-2030

7.1.3.1. U.S.

7.1.3.2. Canada

7.2. Europe

7.2.1. Europe Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, 2020-2030

7.2.2. Europe Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, 2020-2030

7.2.3. Europe Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, 2020-2030

7.2.3.1. Germany

7.2.3.2. Poland

7.2.3.3. France

7.2.3.4. Italy

7.2.3.5. Spain

7.2.3.6. UK

7.2.3.7. Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, 2020-2030

7.3.2. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, 2020-2030

7.3.3. Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, 2020-2030

7.3.3.1. China

7.3.3.2. India

7.3.3.3. Japan

7.3.3.4. Australia

7.3.3.5. Rest of Asia Pacific

7.4. Latin America

7.4.1. Latin America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, (US$ Million) 2020-2030

7.4.2. Latin America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, (US$ Million) 2020-2030

7.4.3. Latin America Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, (US$ Million) 2020-2030

7.4.3.1. Brazil

7.4.3.2. Rest of Latin America

7.5. MEA

7.5.1. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, (US$ Million) 2020-2030

7.5.2. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Products, (US$ Million) 2020-2030

7.5.3. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) By Commercialized Drugs, (US$ Million) 2020-2030

7.5.4. MEA revenue Cell and Gene Therapy Drug Delivery Devices Market revenue (US$ Million) and volume (No. of Units) by country, (US$ Million) 2020-2030

7.5.4.1. South Africa

7.5.4.2. Rest of MEA

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Amgen Inc.

8.2.2. Bausch & Lomb Incorporated.

8.2.3. Becton, Dickinson and Company

8.2.4. Bluebird bio, Inc.

8.2.5. Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)

8.2.6. Dendreon Pharmaceuticals LLC.

8.2.7. Helixmith Co., Ltd (ViroMed Co., Ltd)

8.2.8. Human Stem Cells Institute

8.2.9. Kite Pharma, Inc.

8.2.10. Kolon TissueGene, Inc.

8.2.11. Novartis AG

8.2.12. Orchard Therapeutics plc.

8.2.13. Pfizer, Inc.

8.2.14. Renova Therapeutics

8.2.15. Spark Therapeutics, Inc.

8.2.16. uniQure N.V.

8.2.17. Vericel Corporation

8.3. List of Other Prominent Players

Global Cell and Gene Therapy Drug Delivery Devices Market Segmentation

Global Cell and Gene Therapy Drug Delivery Devices Market Size (Value & Volume) & Forecasts and Trend Analyses, 2019 to 2030 Based on Products

  • Subretinal Injection Cannula
  • Extension Tube
  • Intravenous Catheter
  • Sterile Insulin Syringe
  • Pre-Filled Syringe
  • Infusion Bags

Cell and Gene Therapy Drug Delivery Devices Market

Global Cell and Gene Therapy Drug Delivery Devices Market Size (Value & Volume) & Forecasts and Trend Analyses, 2019 to 2030 Based on Commercialized Drugs

  • Luxturna
  • Kymriah
  • Provenge
  • Zolgensma
  • Yescarta
  • Strimvelis

Global Cell and Gene Therapy Drug Delivery Devices Market Size (Value & Volume) & Forecasts and Trend Analyses, 2019 to 2030 Based on Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Europe Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030

  • U.S.
  • Canada

Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Cell and Gene Therapy Drug Delivery Devices Market Revenue (US$ Million) and Volume (No. of Units) by Country, 2019 to 2030

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

Who are the Key Players in the Global Cell and Gene Therapy Drug Delivery Devices Market?

The Cell and Gene Therapy Drug Delivery Devices Market is expected to grow at a 16.2 % CAGR during the forecast period for 2023-2031.

The Cell and Gene Therapy Drug Delivery Devices Market Size is valued at 134.0 Thousand in 2022 and is predicted to reach 515.0 Thousand by the year 2

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Medical Devices

Select Licence Type
$4182
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach